Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Savara ( (SVRA) ) just unveiled an update.
On October 29, 2025, Savara Inc. announced the pricing of a $130 million public offering of common stock and pre-funded warrants, with the offering expected to close on October 31, 2025. The proceeds from this offering are intended to support general corporate purposes, including clinical development, regulatory approval pursuits, and commercialization activities for MOLBREEVI in the U.S. and EU, potentially impacting Savara’s operational capabilities and market positioning.
The most recent analyst rating on (SVRA) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Savara stock, see the SVRA Stock Forecast page.
Spark’s Take on SVRA Stock
According to Spark, TipRanks’ AI Analyst, SVRA is a Neutral.
Savara’s stock score reflects a company in the developmental stage, with significant financial risks due to its lack of revenue and ongoing cash burn. However, a strong balance sheet and recent financing developments provide some stability. Technical indicators suggest short-term positive momentum, but valuation remains challenging with a negative P/E ratio. The recent loan agreement is a positive step, potentially facilitating future growth and commercialization efforts.
To see Spark’s full report on SVRA stock, click here.
More about Savara
Savara Inc. is a clinical stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Its lead program, MOLBREEVI, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis and is delivered via a proprietary investigational eFlow Nebulizer System.
Average Trading Volume: 1,420,744
Technical Sentiment Signal: Buy
Current Market Cap: $750.1M
For detailed information about SVRA stock, go to TipRanks’ Stock Analysis page.